Crescent Biopharma (CBIO) News
NASDAQ: CBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
13.00+0.09 (+0.70%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CBIO news summary
We found 5 recent headlines mentioning Crescent Biopharma (CBIO): 0 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Seeking Alpha. For price context, CBIO is up 0.70% at $13.00. The most recent story, "Crescent Biopharma GAAP EPS of -$0.90", was published by Seeking Alpha on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Crescent Biopharma headlines
- Crescent Biopharma GAAP EPS of -$0.90Seeking Alpha
- Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business HighlightsCompleted dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy combination…GlobeNewswire
- Crescent Biopharma Announces Grants of Inducement AwardsWALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the…GlobeNewswire
- Crescent Biopharma to Present at November Investor ConferencesWALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next…GlobeNewswire
- Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation completeGlobeNewswire